<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03799614</url>
  </required_header>
  <id_info>
    <org_study_id>HM20012404</org_study_id>
    <nct_id>NCT03799614</nct_id>
  </id_info>
  <brief_title>Vibration Impact on Parkinson's Tremor</brief_title>
  <official_title>Vibration Impact on Parkinson's Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to test the safety, tolerability and efficacy of&#xD;
      vibration (delivered by an experimental device called RMBand that is worn on the subject's&#xD;
      arm) on parkinsonian tremor. The RMBand was developed by Resonate Forward, LLC (RF). This&#xD;
      RMBand is designed to administer a vibration to the wearer to decrease or stop tremor in&#xD;
      persons with Parkinson's disease (PD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation will be completed in one visit at VCU Parkinson's and Movement Disorders&#xD;
      Center. A baseline Movement Disorder Society Unified Parkinson Disease Rating Scale&#xD;
      (MDS-UPDRS) will be taken prior to vibration therapy. The RMBand (experimental device) will&#xD;
      be placed on the arm of the participant to provide the vibration therapy. The MDS-UPDRS Part&#xD;
      III will be repeated both during and after the therapy. Participants will be asked to provide&#xD;
      feedback about the device, the therapy session and how they are feeling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Actual">November 27, 2019</completion_date>
  <primary_completion_date type="Actual">November 27, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS)</measure>
    <time_frame>This rating scale will be used at baseline, 5 minutes after vibration starts, and 5 minutes after vibration is turned off.</time_frame>
    <description>The &quot;Movement Disorder Society Unified Parkinson Disease Rating Scale&quot; (MDS-UPDRS) Part III, only, will be used at baseline, and repeated during vibration and post vibration data collection times. It is a validated scale administered by a clinician, contains 34 items to score between 0 (normal) and 4 (severe). The score range is 0 - 136. It takes ~ 5 minutes to complete. Lower scores are better. This outcome measure will be used to report a change in PD motor symptoms over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Rating for Tremor</measure>
    <time_frame>Data collection times were baseline, 5 minutes after vibration start (vibration duration was 20 minutes), 5 minutes after vibration was stopped. .</time_frame>
    <description>Clinical Rating Scale for Tremor (Fahn, Tolosa, &amp; Marin) assesses severity of tremor symptoms. This scale takes 10-minutes, Items 1 - 14 will be used to report average changes in tremor.&#xD;
Items are rated on a scale of 0=normal to 4=severely abnormal, total summative score range for items 1- 14 points is 0 - 56. Lower scores are better. Total time to complete the Scale for Tremor assessment is 10 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Measurement of Tremor Frequency (Hz)</measure>
    <time_frame>Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.</time_frame>
    <description>This is a device that will objectively measure tremors frequency and amplitude pre, during, and post treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Measurement of Tremor Amplitude (mm).</measure>
    <time_frame>Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.</time_frame>
    <description>This is a device that will objectively measure tremor amplitude pre, during, and post treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Lower dose vibration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RMBand lower dose vibration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher dose vibration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RMBand higher dose vibration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RMBand lower dose</intervention_name>
    <description>Light-weight portable device that delivers low dose vibration to the arm</description>
    <arm_group_label>Lower dose vibration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RMBand higher dose</intervention_name>
    <description>Light-weight portable device that delivers higher dose vibration to the arm</description>
    <arm_group_label>Higher dose vibration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parkinson's disease (PD) as diagnosed by a movement disorder specialist&#xD;
&#xD;
          -  Tremor caused by their Parkinson's disease&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known diagnosis of Parkinson Plus Syndrome&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Other known non-PD cause of tremor&#xD;
&#xD;
          -  Other known non-PD cause of limb dysfunction&#xD;
&#xD;
          -  Presence of implantable cardiac device, severe neuropathy or sensory loss that would&#xD;
             prevent perception of vibration stimulus&#xD;
&#xD;
          -  Non-English speaker&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Pretzer-Aboff, PhD, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <results_first_submitted>November 19, 2020</results_first_submitted>
  <results_first_submitted_qc>November 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03799614/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03799614/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Vibration</title>
          <description>RMBand lower dose vibration&#xD;
RMBand lower dose: Light-weight portable device that delivers low dose vibration to the arm</description>
        </group>
        <group group_id="P2">
          <title>High Dose Vibration</title>
          <description>RMBand higher dose vibration&#xD;
RMBand higher dose: Light-weight portable device that delivers higher dose vibration to the arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lower Dose Vibration</title>
          <description>RMBand lower dose vibration&#xD;
RMBand lower dose: Light-weight portable device that delivers low dose vibration to the arm</description>
        </group>
        <group group_id="B2">
          <title>Higher Dose Vibration</title>
          <description>RMBand higher dose vibration&#xD;
RMBand higher dose: Light-weight portable device that delivers higher dose vibration to the arm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="6.7"/>
                    <measurement group_id="B2" value="67.6" spread="8.4"/>
                    <measurement group_id="B3" value="67.4" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Rating Scale for Tremor, total score</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.13" spread="10.69"/>
                    <measurement group_id="B2" value="18.07" spread="5.22"/>
                    <measurement group_id="B3" value="19.6" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MDS UPDRS II - IV total</title>
          <description>Movement Disorder Society Unified Parkinson Rating Scale, (MDS UPDRS, score for parts II - !V.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.26" spread="16.41"/>
                    <measurement group_id="B2" value="38.47" spread="14.08"/>
                    <measurement group_id="B3" value="41.37" spread="15.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS)</title>
        <description>The &quot;Movement Disorder Society Unified Parkinson Disease Rating Scale&quot; (MDS-UPDRS) Part III, only, will be used at baseline, and repeated during vibration and post vibration data collection times. It is a validated scale administered by a clinician, contains 34 items to score between 0 (normal) and 4 (severe). The score range is 0 - 136. It takes ~ 5 minutes to complete. Lower scores are better. This outcome measure will be used to report a change in PD motor symptoms over time.</description>
        <time_frame>This rating scale will be used at baseline, 5 minutes after vibration starts, and 5 minutes after vibration is turned off.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Vibration</title>
            <description>RMBand low dose vibration&#xD;
RMBand: Light-weight portable device that delivers low dose vibration to the arm</description>
          </group>
          <group group_id="O2">
            <title>Higher Dose Vibration</title>
            <description>RMBand high dose vibration&#xD;
RMBand: Light-weight portable device that delivers higher dose vibration to the arm</description>
          </group>
        </group_list>
        <measure>
          <title>Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS)</title>
          <description>The &quot;Movement Disorder Society Unified Parkinson Disease Rating Scale&quot; (MDS-UPDRS) Part III, only, will be used at baseline, and repeated during vibration and post vibration data collection times. It is a validated scale administered by a clinician, contains 34 items to score between 0 (normal) and 4 (severe). The score range is 0 - 136. It takes ~ 5 minutes to complete. Lower scores are better. This outcome measure will be used to report a change in PD motor symptoms over time.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.67" spread="12.88"/>
                    <measurement group_id="O2" value="27.4" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During vibration treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.67" spread="14.31"/>
                    <measurement group_id="O2" value="27.33" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vibration treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.67" spread="13.67"/>
                    <measurement group_id="O2" value="28.6" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Rating for Tremor</title>
        <description>Clinical Rating Scale for Tremor (Fahn, Tolosa, &amp; Marin) assesses severity of tremor symptoms. This scale takes 10-minutes, Items 1 - 14 will be used to report average changes in tremor.&#xD;
Items are rated on a scale of 0=normal to 4=severely abnormal, total summative score range for items 1- 14 points is 0 - 56. Lower scores are better. Total time to complete the Scale for Tremor assessment is 10 minutes.</description>
        <time_frame>Data collection times were baseline, 5 minutes after vibration start (vibration duration was 20 minutes), 5 minutes after vibration was stopped. .</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lower Dose Vibration</title>
            <description>RMBand lower dose vibration&#xD;
RMBand lower dose: Light-weight portable device that delivers low dose vibration to the arm</description>
          </group>
          <group group_id="O2">
            <title>Higher Dose Vibration</title>
            <description>RMBand higher dose vibration&#xD;
RMBand higher dose: Light-weight portable device that delivers higher dose vibration to the arm</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Rating for Tremor</title>
          <description>Clinical Rating Scale for Tremor (Fahn, Tolosa, &amp; Marin) assesses severity of tremor symptoms. This scale takes 10-minutes, Items 1 - 14 will be used to report average changes in tremor.&#xD;
Items are rated on a scale of 0=normal to 4=severely abnormal, total summative score range for items 1- 14 points is 0 - 56. Lower scores are better. Total time to complete the Scale for Tremor assessment is 10 minutes.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.47" spread="7.94"/>
                    <measurement group_id="O2" value="13.87" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During vibration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.87" spread="8.55"/>
                    <measurement group_id="O2" value="13.20" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vibration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.53" spread="7.98"/>
                    <measurement group_id="O2" value="14.13" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Measurement of Tremor Frequency (Hz)</title>
        <description>This is a device that will objectively measure tremors frequency and amplitude pre, during, and post treatment.</description>
        <time_frame>Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Vibration</title>
            <description>RMBand low dose vibration&#xD;
RMBand: Light-weight portable device that delivers low dose vibration to the arm</description>
          </group>
          <group group_id="O2">
            <title>Higher Dose Vibration</title>
            <description>RMBand high dose vibration&#xD;
RMBand: Light-weight portable device that delivers higher dose vibration to the arm</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Measurement of Tremor Frequency (Hz)</title>
          <description>This is a device that will objectively measure tremors frequency and amplitude pre, during, and post treatment.</description>
          <units>hertz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="1.57"/>
                    <measurement group_id="O2" value="4.51" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During Vibration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="1.13"/>
                    <measurement group_id="O2" value="3.99" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Vibration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="0.87"/>
                    <measurement group_id="O2" value="4.64" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Measurement of Tremor Amplitude (mm).</title>
        <description>This is a device that will objectively measure tremor amplitude pre, during, and post treatment.</description>
        <time_frame>Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Vibration Amplitude</title>
            <description>RMBand low dose vibration&#xD;
RMBand: Light-weight portable device that delivers low dose vibration to the arm,reported in mm.</description>
          </group>
          <group group_id="O2">
            <title>Higher Dose Vibration</title>
            <description>RMBand high dose vibration&#xD;
RMBand: Light-weight portable device that delivers higher dose vibration to the arm</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Measurement of Tremor Amplitude (mm).</title>
          <description>This is a device that will objectively measure tremor amplitude pre, during, and post treatment.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.82"/>
                    <measurement group_id="O2" value="0.43" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During vibration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.72"/>
                    <measurement group_id="O2" value="0.44" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vibration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.75"/>
                    <measurement group_id="O2" value="0.52" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>two hours, during time of study activities</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lower Dose Vibration</title>
          <description>RMBand lower dose vibration&#xD;
RMBand lower dose: Light-weight portable device that delivers low dose vibration (frequency of 80 Hz) to the arm</description>
        </group>
        <group group_id="E2">
          <title>Higher Dose Vibration</title>
          <description>RMBand higher dose vibration&#xD;
RMBand higher dose: Light-weight portable device that delivers higher dose (frequency of 160 Hz) vibration to the arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle tightness</sub_title>
                <description>tightness in muscles in right shoulder and neck</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ingrid Pretzer-Aboff</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-3340</phone>
      <email>iaboff@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

